Welcome to Dermbits! Watch short videos of KOLs answering your questions

thumbnail_dermbits-colorful.png

dermbits-colorful.png

Dermbits

Is there a limitation regarding body surface area with topical ruxolitinib?

Atopic Dermatitis

You. So they have done studies looking at plasma ruxolitinib concentrations after treatment with topical ruxolitinib cream in patients that had atopic dermatitis. And what they saw is that up to 20% of body surface area of involvement with atopic dermatitis and using ruxolithinib as its FDA approved did not lead to much in terms of systemic absorption. So the plasma concentrations after the use of topical ruxolitinib in body surface area of up to 20% was not enough or was not high enough to cause any adverse events in these patients. So I do tell my patients that up to 20% body surface area, they can use topical ruxilitinib. But let's be honest, as dermatologists, when we're looking at a patient that has such a high body surface area, we are giving them, or we're considering systemic therapy at that point. But safe to say, based on sort of data that's out there, if a patient does have a body surface area of involvement up to 20%, it's safe to use topical ruxolitinib because there wouldn't be much in terms of systemic absorption.

Is there a limitation regarding body surface area with topical ruxolitinib?

Related CME